Education
About Us
Working with TipRanks
Follow Us
Affimed (AFMD)
NASDAQ:AFMD
See the Price Targets and Ratings of:
AFMD Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
$11
Buy
1034.02%
Upside
Reiterated
01/15/25
Affimed's Strategic Clinical Advances and Financial Planning Justify Buy RatingWe think shares of AFMD (Overweight rated) are undervalued relative to the opportunities for its de-risked lead asset acimtamig in r/r Hodgkin's lymphoma alone, with significant upside from AFM24 in NSCLC.
Leerink Partners
$6→$5
Buy
415.46%
Upside
Reiterated
12/19/24
Affimed's Potential in Cancer Treatment: Navigating Challenges with Strategic Partnerships
H.C. Wainwright
$10→$7
Buy
621.65%
Upside
Reiterated
12/18/24
Affimed price target lowered to $7 from $10 at H.C. WainwrightAffimed price target lowered to $7 from $10 at H.C. Wainwright
Laidlaw
$15→$25
Buy
2477.32%
Upside
Reiterated
06/12/24
Affimed Therapeutics (AFMD) PT Raised to $25 at LaidlawLaidlaw analyst Yale Jen raised the price target on Affimed Therapeutics (NASDAQ: AFMD) to $25.00 (from $15.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
$11
Buy
1034.02%
Upside
Reiterated
01/15/25
Affimed's Strategic Clinical Advances and Financial Planning Justify Buy RatingWe think shares of AFMD (Overweight rated) are undervalued relative to the opportunities for its de-risked lead asset acimtamig in r/r Hodgkin's lymphoma alone, with significant upside from AFM24 in NSCLC.
Leerink Partners
$6→$5
Buy
415.46%
Upside
Reiterated
12/19/24
Affimed's Potential in Cancer Treatment: Navigating Challenges with Strategic Partnerships
H.C. Wainwright
$10→$7
Buy
621.65%
Upside
Reiterated
12/18/24
Affimed price target lowered to $7 from $10 at H.C. WainwrightAffimed price target lowered to $7 from $10 at H.C. Wainwright
Laidlaw
$15→$25
Buy
2477.32%
Upside
Reiterated
06/12/24
Affimed Therapeutics (AFMD) PT Raised to $25 at LaidlawLaidlaw analyst Yale Jen raised the price target on Affimed Therapeutics (NASDAQ: AFMD) to $25.00 (from $15.00) while maintaining a Buy rating.
Best Analysts Covering Affimed
Which Analyst Should I Follow If I Want to Buy AFMD and Sell After:
1 Month
xxx
Success Rate
7/20 ratings generated profit
Average Return
-5.24%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.00% of your transactions generating a profit, with an average return of -5.24% per trade.
3 Months
xxx
Success Rate
4/20 ratings generated profit
Average Return
-18.98%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -18.98% per trade.
1 Year
Success Rate
1/20 ratings generated profit
Average Return
-52.73%
reiterated a buy rating 4 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -52.73% per trade.
2 Years
xxx
Success Rate
1/20 ratings generated profit
Average Return
-74.34%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 5.00% of your transactions generating a profit, with an average return of -74.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AFMD Analyst Recommendation Trends
Rating
Jun 24
Sep 24
Nov 24
Dec 24
Jan 25
Strong Buy
6
6
5
9
9
Buy
6
9
9
5
2
Hold
2
3
3
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
18
17
16
14
Each month's total comprises the sum of three months' worth of ratings.
AFMD Stock Forecast FAQ
What is AFMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Affimed’s 12-month average price target is 11.00.
What is AFMD’s upside potential, based on the analysts’ average price target?
Affimed has 1034.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AFMD a Buy, Sell or Hold?
Affimed has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Affimed’s price target?
The average price target for Affimed is 11.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 1034.02% Increase from the current price of $0.97.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 1034.02% Increase from the current price of $0.97.
What do analysts say about Affimed?
Affimed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of AFMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.